Volume 19, Issue 4, Pages 629-631 (April 2011) Sodium Iodide Symporter SPECT Imaging of a Patient Treated With Oncolytic Adenovirus Ad5/3-Δ24-hNIS  Maria Rajecki, Aki Kangasmäki, Leena Laasonen, Sophie Escutenaire, Tanja Hakkarainen, Jarmo Haukka, Ari Ristimäki, Kalevi Kairemo, Lotta Kangasniemi, Timo Kiljunen, Timo Joensuu, Sari Pesonen, Akseli Hemminki  Molecular Therapy  Volume 19, Issue 4, Pages 629-631 (April 2011) DOI: 10.1038/mt.2011.31 Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 SPEC-CT imaging of Ad5/3-24-hNIS. (a) A whole-body scan (Siemens Symbia T2, Siemens Medical Solutions, Erlangen, Germany) showing the distribution of 123I 4 hours after 123I injection and 25 hours after intratumoral Ad5/3-24–human sodium iodide symporter (hNIS) injection. Virus was produced by Oncos Therapeutics (Helsinki, Finland). The injection was administered into the tumor mass in the lesser pelvis and into a liver metastasis (dotted lines). The lower panel shows a single-photon emission-computed tomography (SPECT)-computed tomography scan of the pelvic tumor (dotted lines) at the same time point. Only background activity is detected. The images are representative of all the imaging time points, suggesting that with the sensitivity of SPECT, hNIS expression originating from Ad5/3-24-hNIS could not be detected. As positive controls for the imaging, the thyroid, stomach, salivary glands, and pyelostoma catheters can be seen (arrows). (b) Viral load in patient serum as detected by quantitative polymerase chain reaction. Increase on days 1 and 2 suggests virus replication. (c) Hematoxylin–eosin staining of a pretreatment biopsy from the tumor of the lesser pelvis showing 60% poorly differentiated carcinoma,35% fibrotic stroma (arrows), and 5 % necrotic tissue (thick arrowhead). Molecular Therapy 2011 19, 629-631DOI: (10.1038/mt.2011.31) Copyright © 2011 The American Society of Gene & Cell Therapy Terms and Conditions